ZA200109263B - Substituted phenylcyclohexane carboxylic acid amides that have an adenosine uptake inhibiting. - Google Patents

Substituted phenylcyclohexane carboxylic acid amides that have an adenosine uptake inhibiting.

Info

Publication number
ZA200109263B
ZA200109263B ZA200109263A ZA200109263A ZA200109263B ZA 200109263 B ZA200109263 B ZA 200109263B ZA 200109263 A ZA200109263 A ZA 200109263A ZA 200109263 A ZA200109263 A ZA 200109263A ZA 200109263 B ZA200109263 B ZA 200109263B
Authority
ZA
South Africa
Prior art keywords
carboxylic acid
acid amides
adenosine uptake
uptake inhibiting
phenylcyclohexane carboxylic
Prior art date
Application number
ZA200109263A
Other languages
English (en)
Inventor
Wolf-Dietrich Freund
Stephen Lensky
Muller Stephan Nicholas
Holger Paulsen
Jorg Keldenich
Ervin Horvath
Joachim Schumacher
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of ZA200109263B publication Critical patent/ZA200109263B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA200109263A 1999-05-29 2001-11-09 Substituted phenylcyclohexane carboxylic acid amides that have an adenosine uptake inhibiting. ZA200109263B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19924818A DE19924818A1 (de) 1999-05-29 1999-05-29 Substituierte Phenylcyclohexancarbonsäureamide

Publications (1)

Publication Number Publication Date
ZA200109263B true ZA200109263B (en) 2003-01-29

Family

ID=7909712

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200109263A ZA200109263B (en) 1999-05-29 2001-11-09 Substituted phenylcyclohexane carboxylic acid amides that have an adenosine uptake inhibiting.

Country Status (36)

Country Link
US (2) US6716849B1 (no)
EP (1) EP1185516B1 (no)
JP (1) JP2003500475A (no)
KR (1) KR20020003397A (no)
CN (1) CN1200932C (no)
AR (1) AR024100A1 (no)
AT (1) ATE238997T1 (no)
AU (1) AU765752B2 (no)
BG (1) BG106107A (no)
BR (1) BR0011061A (no)
CA (1) CA2375186A1 (no)
CZ (1) CZ20014288A3 (no)
DE (2) DE19924818A1 (no)
DK (1) DK1185516T3 (no)
EE (1) EE200100634A (no)
ES (1) ES2197870T3 (no)
GT (1) GT200000083A (no)
HK (1) HK1048810A1 (no)
HN (1) HN2000000072A (no)
HR (1) HRP20010955A2 (no)
HU (1) HUP0201350A3 (no)
IL (1) IL146392A0 (no)
MA (1) MA25414A1 (no)
MX (1) MXPA01012241A (no)
MY (1) MY122576A (no)
NO (1) NO20015810L (no)
PE (1) PE20010167A1 (no)
PL (1) PL352101A1 (no)
PT (1) PT1185516E (no)
RU (1) RU2246490C9 (no)
SI (1) SI1185516T1 (no)
SK (1) SK17052001A3 (no)
SV (1) SV2004000087A (no)
UA (1) UA73126C2 (no)
WO (1) WO2000073275A1 (no)
ZA (1) ZA200109263B (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1834090B (zh) * 2005-03-18 2011-06-29 中国科学院上海药物研究所 苯并咪唑类化合物、其制备方法以及用途
AU2009259440B2 (en) * 2008-06-16 2014-05-29 Boehringer Ingelheim International Gmbh Method for producing an intermediate product of dabigatran etexilate
JP6359008B2 (ja) 2012-06-11 2018-07-18 ユーシービー バイオファルマ エスピーアールエル Ｔｎｆ−アルファ調節ベンゾイミダゾール
BR112021009988A2 (pt) * 2018-11-25 2021-08-17 Tnt Medical Corporation composto de fórmula (i), ou um n-óxido deste, ou um sal, solvato, polimorfo, tautômero, estereoisômero farmaceuticamente aceitável, uma forma isotópica, ou um pró-fármaco do dito composto de fórmula (i) ou n-óxido deste, composição farmacêutica, e método de tratamento de uma doença neoplásica

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2685918B1 (fr) * 1992-01-08 1995-06-23 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
DE4221009A1 (de) * 1992-06-26 1994-01-05 Bayer Ag Imidazolyl-substituierte Cyclohexanderivate
ATE174913T1 (de) * 1992-07-31 1999-01-15 Bristol Myers Squibb Co Diphenyl oxazole-, thiazole- und imidazole- derivate als inhibitoren der wiederaufnahme des adenosins
DE4304455A1 (de) * 1993-02-15 1994-08-18 Bayer Ag Heterocyclisch substituierte Phenyl-cyclohexan-carbonsäurederivate
DE4401893A1 (de) * 1994-01-24 1995-07-27 Bayer Ag Substituierte Arylharnstoffe
HRP960015B1 (en) * 1995-02-01 2000-12-31 Bayer Ag Substituted indole derivatives
DE19503160A1 (de) * 1995-02-01 1996-08-08 Bayer Ag Verwendung von Phenylcyclohexylcarbonsäureamiden

Also Published As

Publication number Publication date
CZ20014288A3 (cs) 2002-03-13
EP1185516B1 (de) 2003-05-02
AU4405500A (en) 2000-12-18
HUP0201350A3 (en) 2003-05-28
HUP0201350A2 (en) 2002-08-28
ATE238997T1 (de) 2003-05-15
US6716849B1 (en) 2004-04-06
JP2003500475A (ja) 2003-01-07
RU2246490C9 (ru) 2005-09-20
DK1185516T3 (da) 2003-08-11
NO20015810L (no) 2002-01-25
CA2375186A1 (en) 2000-12-07
SK17052001A3 (sk) 2002-06-04
CN1365356A (zh) 2002-08-21
HN2000000072A (es) 2001-02-02
HRP20010955A2 (en) 2003-08-31
UA73126C2 (en) 2005-06-15
BG106107A (bg) 2002-05-31
DE50001982D1 (de) 2003-06-05
RU2246490C2 (ru) 2005-02-20
CN1200932C (zh) 2005-05-11
AR024100A1 (es) 2002-09-04
MY122576A (en) 2006-04-29
MA25414A1 (fr) 2002-04-01
SV2004000087A (es) 2004-05-07
MXPA01012241A (es) 2002-08-12
PL352101A1 (en) 2003-07-28
SI1185516T1 (en) 2003-10-31
IL146392A0 (en) 2002-07-25
KR20020003397A (ko) 2002-01-12
PT1185516E (pt) 2003-09-30
PE20010167A1 (es) 2001-04-25
US20040186106A1 (en) 2004-09-23
ES2197870T3 (es) 2004-01-16
HK1048810A1 (zh) 2003-04-17
EP1185516A1 (de) 2002-03-13
NO20015810D0 (no) 2001-11-28
EE200100634A (et) 2003-02-17
WO2000073275A1 (de) 2000-12-07
GT200000083A (es) 2001-11-17
DE19924818A1 (de) 2000-11-30
AU765752B2 (en) 2003-09-25
BR0011061A (pt) 2002-03-05

Similar Documents

Publication Publication Date Title
GB2351077B (en) Improved acid corrosion inhibitor
ZA99567B (en) Aryl-acrylic acid esters.
GB9923804D0 (en) Electronic commerce system
GB2357664B (en) Electronic commerce system
MXPA02003669A (es) Modificacion del tiempo de floracion.
EP1318726A4 (en) CLEANING AGENTS FOR MARINADES
MXPA03005151A (es) Sistema de sujecion magnetica.
HK1054038A1 (en) Substituted n-benzyl-indol-3-yl gloyoxylic acid derivatives having an antitumural effect
HK1034969A1 (en) Dihydroxyhexanoic acid derivatives.
ZA979756B (en) Substituted 4-biphenyl-4-hydroxybutyric acid derivatives as matrix metalloprotease inhibitors.
MXPA01012714A (es) Sistema de comercio electronico.
ZA200109263B (en) Substituted phenylcyclohexane carboxylic acid amides that have an adenosine uptake inhibiting.
MXPA01007977A (es) Complemento alimenticio de cromo-acido carboxilico.
ZA200108894B (en) Substituted phenylcyclohexane carboxylic acid amides and their use as adenosine uptake inhibitors.
ZA974033B (en) Substituted 4-arylbutyric acid derivatives as matrix metalloprotease inhibitors.
AP2004003005A0 (en) Novel alpha-oxygenated or alpha-thiolated carboxylic acid penethylamide derivatives.
HK1045740A1 (en) E commerce system.
ZA200003617B (en) Trailer noseweight indicator.
IL149237A0 (en) Electronic commerce system
ZA987000B (en) Tow bar.
ZA200106546B (en) Chromium-carboxylic acid free supplement.
ZA200006202B (en) Electronic commerce system.
GB9912903D0 (en) Fold-away tow bar
GB0026419D0 (en) Carboxylic acid complexes
ZA200000221B (en) Trailer.